Abstract
Objectives: A screening tool for Cystic Fibrosis Diabetes (CFD) is in use at the Norfolk and Norwich University Hospital (NNUH) to improve cost-effectiveness and ensure appropriate allocation of limited time and resources within the CF team. The tool involves initial screening using 3-point oral glucose tolerance testing (OGTT) alongside HbA1c. When this is not possible, HbA1c is used in isolation to highlight patients for additional monitoring. The results are assessed and patients are categorised for further discussion, which may lead to testing using continuous glucose monitoring (CGM) or finger prick glucose measurements, or allocated to yearly re-screening. The aim of this audit was to explore the use and effectiveness of this tool.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
